Boston Advisors’s Heron Therapeutics HRTX Stock Holding History

Boston Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.37M	Buy	73,869 +24,293	+49%	+$447K	0.07%	337
2019 Q2	$922K	Sell	49,576 -84,983	-63%	-$1.7M	0.05%	379
2019 Q1	$3.29M	Buy	134,559 +109,819	+444%	+$2.87M	0.17%	167
2018 Q4	$642K	Buy	24,740 +2,595	+12%	+$71.3K	0.04%	411
2018 Q3	$701K	Buy	22,145 +3,040	+16%	+$113K	0.03%	434
2018 Q2	$742K	Sell	19,105 -8,550	-31%	-$272K	0.02%	433
2018 Q1	$763K	Buy	+27,655	New	+$627K	0.02%	422

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Boston Advisors's HRTX Position: Q3 2019 in Review

Boston Advisors increased its Heron Therapeutics (HRTX) stake by 49% in Q3 2019, buying an estimated $447K and bringing the position to 73,869 shares worth $1.37M. The position accounts for 0.07% of the portfolio, ranked #337.

Boston Advisors first reported a position in HRTX in Q1 2018 and has held it in 7 quarters since. The position peaked at $3.29M in Q1 2019. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

Boston Advisors held 73,869 shares of Heron Therapeutics worth $1.37M as of Q3 2019.
Boston Advisors bought 24,293 Heron Therapeutics shares in Q3 2019, an estimated $447K.
Heron Therapeutics made up 0.07% of Boston Advisors's portfolio in Q3 2019, its #337 holding.
Boston Advisors first reported a position in Heron Therapeutics in Q1 2018 and has held it in 7 quarters since.
Boston Advisors's Heron Therapeutics position peaked at $3.29M in Q1 2019.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.